<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Exp Ther Med</journal-id><journal-id journal-id-type="iso-abbrev">Exp Ther Med</journal-id><journal-id journal-id-type="publisher-id">ETM</journal-id><journal-title-group><journal-title>Experimental and Therapeutic Medicine</journal-title></journal-title-group><issn pub-type="ppub">1792-0981</issn><issn pub-type="epub">1792-1015</issn><publisher><publisher-name>D.A. Spandidos</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28123464</article-id><article-id pub-id-type="pmc">5244777</article-id><article-id pub-id-type="doi">10.3892/etm.2016.3924</article-id><article-id pub-id-type="publisher-id">ETM-0-0-3924</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Effect of a small dose of aspirin on quantitative test of 24-h urinary protein in patients with hypertension in pregnancy</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Fangmei</given-names></name><xref ref-type="aff" rid="af1-etm-0-0-3924">1</xref></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Huili</given-names></name><xref ref-type="aff" rid="af1-etm-0-0-3924">1</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Guiyun</given-names></name><xref ref-type="aff" rid="af2-etm-0-0-3924">2</xref></contrib><contrib contrib-type="author"><name><surname>Zou</surname><given-names>Kun</given-names></name><xref ref-type="aff" rid="af1-etm-0-0-3924">1</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Yana</given-names></name><xref ref-type="aff" rid="af1-etm-0-0-3924">1</xref><xref rid="c1-etm-0-0-3924" ref-type="corresp"/></contrib></contrib-group><aff id="af1-etm-0-0-3924"><label>1</label>Department of Obstetrics and Gynecology, Jinan Central Hospital, Shandong University, Jinan, Shandong 250013, P.R. China</aff><aff id="af2-etm-0-0-3924"><label>2</label>Department of Obstetrics and Gynecology, The First People's Hospital of Jinan, Jinan, Shandong 250000, P.R. China</aff><author-notes><corresp id="c1-etm-0-0-3924"><italic>Correspondence to</italic>: Dr Yana Chen, Department of Obstetrics and Gynecology, Jinan Central Hospital, Shandong University, 44 Wenhua Xi Road Jinan, Shandong 250013, P.R. China, E-mail: <email>mifdpmx51081@163.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>1</month><year>2017</year></pub-date><pub-date pub-type="epub"><day>22</day><month>11</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>22</day><month>11</month><year>2016</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>13</volume><issue>1</issue><fpage>37</fpage><lpage>40</lpage><history><date date-type="received"><day>25</day><month>1</month><year>2016</year></date><date date-type="accepted"><day>19</day><month>8</month><year>2016</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; Liu et al.</copyright-statement><copyright-year>2016</copyright-year><license license-type="open-access"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivs License</ext-link>, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.</license-p></license></permissions><abstract><p>The aim of the present study was to determine the effect of a small dose of aspirin on a quantitative test of 24-h urinary protein in patients with hypertension in pregnancy. In total, 224 patients with hypertension in pregnancy were continuously selected and were randomly divided into the control group (50 cases with conventional therapy), aspirin 50 mg/day group (60 cases), aspirin 75 mg/day group (58 cases), and aspirin 100 mg/day group (56 cases). Clinical effects were compared from 16 gestational weeks to childbirth. According to the comparison in the four groups, there was no statistical difference in the mean arterial pressure, pre-eclampsia rate, gestational weeks, and caesarean section rate (p&#x0003e;0.05). The 24-h urinary protein and endothelin-1 (ET-1) level were significantly decreased following treatment, and were less than the control and 50 mg/day groups. The superoxide dismutase (SOD) level was significantly increased, and higher than the control and 50 mg/day groups. In terms of the 75 and 100 mg/day, control and 50 mg/day groups, there was no statistical difference (p&#x0003e;0.05). A comparison of the complication rate in the four groups of fetuses during the perinatal period, no statistical difference was observed (p&#x0003e;0.05). Thus, the results show that, regarding patients with hypertension in pregnancy, 75 mg/day aspirin can decrease the 24-h urinary protein, SOD, and ET-1 level. However, the results remain to be confirmed to improve maternal and infant outcome in delivery.</p></abstract><kwd-group><kwd>aspirin</kwd><kwd>hypertension in pregnancy</kwd><kwd>24-h urinary protein</kwd><kwd>superoxide dismutase</kwd><kwd>endothelin-1</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Hypertension in pregnancy is a common disease that exhibits clinical characteristics including hypertension, edema, albuminuria, twitch, coma, heart and renal failure, and even maternal-fetal death (?). The 2013 guidelines for hypertension in pregnancy released by ACOG recommends that it is essential to have a quantitative test of 24-h urinary protein and diagnosis of pre-eclampsia (<xref rid="b1-etm-0-0-3924" ref-type="bibr">1</xref>). Additionally, with biochemical indices such as superoxide dismutase (SOD) and endothelin-1 (ET-1), the accuracy of diagnosis may be highly improved in the early stage of pre-eclampsia.</p><p>For patients at high risk of suffering from pre-eclampsia a small dose of aspirin (60&#x02013;80 mg/day) is considered safe and effective. Although recording of the starting time and administration of aspirin to patients with hypertension in pregnancy is a recent phenomenon in China, previous findings have shown that aspirin (50 mg/day) is definitely beneficial to reduce the incidence of pre-eclampsia and intracranial hemorrhage of fetus (<xref rid="b2-etm-0-0-3924" ref-type="bibr">2</xref>). In addition, aspirin at a dose of 100 mg/day may be more beneficial than 50 mg/day without increasing complications during the perinatal period (<xref rid="b3-etm-0-0-3924" ref-type="bibr">3</xref>).</p><p>The present randomized, double-blind and clinical control study was performed to determine whether a small dose of aspirin is useful to patients with hypertension in pregnancy.</p></sec><sec sec-type="subjects|methods"><title>Patients and methods</title><p>A total of 224 patients with hypertension in pregnancy were successively selected from October, 2012 to October, 2015, at the Jinan Central Hospital (Shandong, China). The inclusion criteria for the study were: i) &#x02265;18 but &#x0003c;50 years of age; ii) in accordance with 2013 standards for hypertension in pregnancy issued by ACOG, but with high risk of pre-eclampsia such as &#x0003e;40 years, obesity, chronic hypertension, chronic kidney disease, type 1 or 2 diabetes mellitus, family history of pre-eclampsia, previous pregnancy along with pre-eclampsia, thrombosis history, and systemic lupus erythematosus; iii) single birth; and iv) no past history of having aspirin and anticoagulant medications such as warfarin, and no complications such as rheumatic disease and chronic atrial fibrillation that require ingesting aspirin or warfarin. The exclusion criteria were: i) artificial insemination; ii) coagulation disorders; iii) hard to control medication for hypertension in pregnancy; iv) an allergy to aspirin; and v) bad compliance.</p><p>The present study was approved by the ethics committee of the Jinan Central Hospital. Written informed consent was obtained from the patients. According to the order of hospitalization, patients were randomly divided into the control group (50 cases with conventional therapy), aspirin 50 mg/day group (60 cases), aspirin 70 mg/day group (58 cases), and aspirin 100 mg/d group (56 cases). In the control group, patients were 22&#x02013;35 years of age, with an average of 26.7&#x000b1;5.5 years. The gestational weeks were 10&#x02013;15 weeks, with an average of 14.7&#x000b1;3.2 weeks. BMI was 25.5&#x02013;35.7 kg/m<sup>2</sup>, with an average of 32.6&#x000b1;7.5 kg/m<sup>2</sup>. Concerning the 50 mg/day group, patients were 23&#x02013;36 years, with an average of 27.2&#x000b1;5.8 years. The gestational weeks were 11&#x02013;16 weeks, with an average of 15&#x000b1;3.6 weeks. BMI was 25.3&#x02013;36.2 kg/m<sup>2</sup>, with an average of 34.1&#x000b1;7.7 kg/m<sup>2</sup>. In the 75 mg/day group, patients were 24&#x02013;33 years, with an average of 26.5&#x000b1;5.3 years. The gestational weeks were 12&#x02013;15.5 weeks, with an average of 13.8&#x000b1;3.9 weeks. BMI was 23.8&#x02013;35.9 kg/m<sup>2</sup>, with an average of 32.7&#x000b1;5.9 kg/m<sup>2</sup>. In the 100 mg/day group, patients were 23&#x02013;34 years, with an average of 25.5&#x000b1;4.6 years. The gestational weeks were 9&#x02013;15.6 weeks, with an average of 14.4&#x000b1;5.2 weeks. BMI was 23.5&#x02013;34.7 kg/m<sup>2</sup>, with an average of 31.8&#x000b1;6.9 kg/m<sup>2</sup>. A comparison of the four groups with regard to age, gestational weeks and BMI, yielded no statistical significant difference (p&#x0003e;0.05).</p><sec><title/><sec><title>Treatment therapy</title><p>On the basis of the guideline, conventional therapy included moderate training. Calcium was recommended if there was a lack of the basic volume thereof. Patients with mild hypertension in pregnancy (continuous blood pressure &#x0003c;160/110 mmHg) or pre-eclampsia were not recommended to have a hypotensor. If patients suffered from pre-eclampsia with severe hypertension in pregnancy (continuous blood pressure &#x02265;160/110 mmHg), anti-hypertensive treatment was considered a good choice. For example, patients were initially administered anti-hypertensive drugs orally, followed by intravenous injection. Magnesium sulfate was also administered in combination if required. However, vitamin C and E without salt restriction were not recommended. Termination of pregnancy had to be performed in time, and the manner of delivery was required to be in accordance with gestational weeks, fetal presentation, cervical ripeness and maternal-fetal situation. Anti-hypertensive treatment was performed when continuous hypertension was &#x02265;150/100 mmHg after delivery. If hypertension was &#x02265;160/110 mmHg, patients were required to undergo treatment within an hour.</p><p>From 16 gestational weeks to childbirth, aspirin from Bayer (Berlin, Germany) (100 mg/tablet, 30 tablets in all) was taken before bedtime. In addition, blood routine and blood coagulation were monitored regularly (once per month) in case of abnormal reaction. Patients accepted drug withdrawal immediately when abnormal reaction occurred.</p></sec><sec><title>Observation index</title><p>Patients were divided into four groups to determine differences in MAP, pre-eclampsia incidence, gestational weeks and the caesarean section rate, test of 24-h urinary protein, SOD and ET-1, and complications during the perinatal period. For SOD and ET-1 peripheral blood of 5 ml was collected on an empty stomach. The upper stratum was removed by centrifugation at 2,800 &#x000d7; g after 30 min, and kept at 4&#x000b0;C for the test. For SOD the xanthine oxidase method was used, whereas radioimmunoassay was used for ET-1. Kits were purchased from R&#x00026;D Systems, Inc. (Minneapolis, MN, USA), and the manufacturer's instructions were strictly followed.</p></sec><sec><title>Statistical analysis</title><p>SPSS 20.0 software (Chicago, IL, USA) was used for the statistical analysis. Measurement data were presented as mean &#x000b1; standard deviation. ANOVA analysis was used for comparison between groups with with preset &#x003b1; &#x0003c;0.05 for significance. For comparison between two groups, the LSD and Bonferroni tests were used to determine any significant difference (1/4 &#x003b1;&#x0003c;0.013). For comparisons before and after the treatment, the paired-sample t-test was used. Enumeration data were presented as percentage and the &#x003c7;<sup>2</sup> test was used for data analysis. There was statistical difference when p&#x0003c;0.05.</p></sec></sec></sec><sec sec-type="results"><title>Results</title><sec><title/><sec><title>Comparison of MAP, pre-eclampsia rate, gestational weeks and caesarean section</title><p>No statistical difference for MAP, pre-eclampsia, gestational weeks and caesarean section was observed following a comparison in the four groups (p&#x0003e;0.05) (<xref rid="tI-etm-0-0-3924" ref-type="table">Table I</xref>).</p></sec><sec><title>Comparison of 24-h urinary protein, SOD and ET-1</title><p>A comparison of the 24-h urinary protein, SOD and ET-1 indicated no statistical difference before treatment (p&#x0003e;0.05). After treatment, the 24-h urinary protein and ET-1 was decreased significantly, lower than the control and 50 mg/day groups. By contrast, SOD was increased, and was higher than the control and 50 mg/day groups. These results were statistically different (p&#x0003c;0.05). No statistical difference following for the 75 and 100 mg/day, control and 50 mg/day groups (p&#x0003e;0.05) was found (<xref rid="tII-etm-0-0-3924" ref-type="table">Table II</xref>).</p></sec><sec><title>Comparison in complications during the perinatal period</title><p>No statistical difference following a comparison of complications during the perinatal period of the four groups was found (<xref rid="tIII-etm-0-0-3924" ref-type="table">Table III</xref>).</p></sec></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>Previous findings have shown that using aspirin early is beneficial for pregnant women with high risk of pre-eclampsia (<xref rid="b4-etm-0-0-3924" ref-type="bibr">4</xref>). However, this is not the case for patients at low risk. Additionally, a small dose of aspirin does not lead to bleeding and placental abruption, and is considered the first choice of treatment to prevent the problem in pregnant women who are at high risk of pre-eclampsia (<xref rid="b4-etm-0-0-3924" ref-type="bibr">4</xref>). Nevertheless, there is currently no concensus on the appropriate dose of aspirin to be used. The 2010 guidelines for hypertension in pregnancy released by NICE suggested that it was safe and effective for women with pre-eclampsia at middle and high risk should take 75 mg of aspirin daily from 12 gestational weeks to childbirth (<xref rid="b5-etm-0-0-3924" ref-type="bibr">5</xref>). Previous findings have shown no statistical differences between the incidence of bleeding before and after delivery with aspirin (<xref rid="b6-etm-0-0-3924" ref-type="bibr">6</xref>). On the basis of different doses of aspirin in clinical treatment, it has been concluded that taking &#x0003e;150 mg of aspirin per day may lead to a high incidence of bleeding after delivery (<xref rid="b7-etm-0-0-3924" ref-type="bibr">7</xref>). Thus, a small dose of aspirin may affect the prevention of pre-eclampsia without increasing the risk of bleeding in mother and infant.</p><p>Oxidative stress is associated with the mechanism of pre-eclampsia (<xref rid="b8-etm-0-0-3924" ref-type="bibr">8</xref>). Antioxidants such as vitamin C and E may be useful in the prevention of pre-eclampsia. Taking vitamin C and E through lots of random tests and case-control study on placebo has been shown not to be useful (<xref rid="b9-etm-0-0-3924" ref-type="bibr">9</xref>). Urinary protein is a sign of early hypertensive kidney lesion and of disease progression as in the case of pre-eclampsia (<xref rid="b10-etm-0-0-3924" ref-type="bibr">10</xref>). Different levels of urinary protein are positively correlated with the degree of blood pressure (<xref rid="b11-etm-0-0-3924" ref-type="bibr">11</xref>). An increase of urinary protein may lead to the ultrastructure of the local spherule-tubule cell in kidney to change, and the electrical load to be raised. Furthermore, urinary protein may leak out under such poor circulation. Additionally, there is disorder in the local part of the kidney, whole oxygen-free radical metabolism, and vascular endothelial cell (<xref rid="b12-etm-0-0-3924" ref-type="bibr">12</xref>). Active metabolism in placenta, higher oxygen consumption, more oxygen-free radicals, and a balance of oxidation and anti-oxidation are major factors in the prevention of pre-eclampsia (<xref rid="b13-etm-0-0-3924" ref-type="bibr">13</xref>). SOD is a free radical scavenger that lies in the cells of aerobic metabolism. It plays a role in controlling the balance of creating and removing free radicals (<xref rid="b14-etm-0-0-3924" ref-type="bibr">14</xref>). Previous findings have shown that a certain dose of aspirin (75 and 100 mg) may raise the SOD level, relieve oxidation reactions and improve metabolism in urinary protein (<xref rid="b15-etm-0-0-3924" ref-type="bibr">15</xref>).</p><p>Owing to feeding cells, the placenta is likely to undergo hypoxia and ischemia and then release a variety of inflammatory factors including ET-1 with vasoconstriction. In addition, with the damage in vascular endothelial cells, internal and external coagulation mechanism may function. Thus, platelet aggregation is associated with thrombus formation (<xref rid="b16-etm-0-0-3924" ref-type="bibr">16</xref>). ET-1 lies in endothelial cells, which is the most vasoactive substance. It increases obviously during the middle and late pregnancy of normal pregnant women, but also increases in women with hypertension. There is a close relationship with pre-eclampsia in incidence and severity (<xref rid="b17-etm-0-0-3924" ref-type="bibr">17</xref>). Aspirin is important in retarding platelet aggregation and thrombus formation by inhibiting the activity of epoxidase, interfering arachidonic acid to TXA2 and increasing PG12 (<xref rid="b18-etm-0-0-3924" ref-type="bibr">18</xref>). Thus, a certain dose of aspirin (75 and 100 mg) plays an important role in reducing ET-1 and improving metabolism in urinary protein.</p><p>The present findings suggest that there was no statistical significance with regard to MAP, pre-eclampsia, gestational weeks and the caesarean section rate in the four groups studied. Although a certain dose of aspirin can reduce urinary protein, SOD and ET-1, whether it can change the clinical outcome is not clear. Different from the previous studies, which identifed a small dose of aspirin as being capable of preventing middle and high risk pre-eclampsia, different races and samples were also taken into account in the current study. No statistical significance in the incidence of complications during the perinatal period was observed. Thus, no association between the two factors may exist.</p><p>In conclusion, 75 mg of aspirin daily can reduce 24-h urinary protein, SOD, and ET-1 in those patients with hypertension in pregnancy. Nevertheless, more studies are required to determine whether it can improve delivery outcome of mother and infant.</p></sec></body><back><ref-list><title>References</title><ref id="b1-etm-0-0-3924"><label>1</label><element-citation publication-type="journal"><collab collab-type="corp-author">American College of Obstetricians and Gynecologists; Task Force on Hypertension in Pregnancy</collab><article-title>Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy</article-title><source>Obstet Gynecol</source><volume>122</volume><fpage>1122</fpage><lpage>1131</lpage><year>2013</year><pub-id pub-id-type="pmid">24150027</pub-id></element-citation></ref><ref id="b2-etm-0-0-3924"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duley</surname><given-names>L</given-names></name><name><surname>Henderson-Smart</surname><given-names>DJ</given-names></name><name><surname>Meher</surname><given-names>S</given-names></name><name><surname>King</surname><given-names>JF</given-names></name></person-group><article-title>Antiplatelet agents for preventing pre-eclampsia and its complications</article-title><source>Cochrane Database Syst Rev</source><volume>18</volume><fpage>CD004659</fpage><year>2007</year></element-citation></ref><ref id="b3-etm-0-0-3924"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bujold</surname><given-names>E</given-names></name><name><surname>Roberge</surname><given-names>S</given-names></name><name><surname>Lacasse</surname><given-names>Y</given-names></name><name><surname>Bureau</surname><given-names>M</given-names></name><name><surname>Audibert</surname><given-names>F</given-names></name><name><surname>Marcoux</surname><given-names>S</given-names></name><name><surname>Forest</surname><given-names>JC</given-names></name><name><surname>Gigu&#x000e8;re</surname><given-names>Y</given-names></name></person-group><article-title>Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: A meta-analysis</article-title><source>Obstet Gynecol</source><volume>116</volume><fpage>402</fpage><lpage>414</lpage><year>2010</year><pub-id pub-id-type="doi">10.1097/AOG.0b013e3181e9322a</pub-id><pub-id pub-id-type="pmid">20664402</pub-id></element-citation></ref><ref id="b4-etm-0-0-3924"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossi</surname><given-names>AC</given-names></name><name><surname>Mullin</surname><given-names>PM</given-names></name></person-group><article-title>Prevention of pre-eclampsia with low-dose aspirin or vitamins C and E in women at high or low risk: a systematic review with meta-analysis</article-title><source>Eur J Obstet Gynecol Reprod Biol</source><volume>158</volume><fpage>9</fpage><lpage>16</lpage><year>2011</year><pub-id pub-id-type="doi">10.1016/j.ejogrb.2011.04.010</pub-id><pub-id pub-id-type="pmid">21641104</pub-id></element-citation></ref><ref id="b5-etm-0-0-3924"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Redman</surname><given-names>CW</given-names></name></person-group><article-title>Hypertension in pregnancy: the NICE guidelines</article-title><source>Heart</source><volume>97</volume><fpage>1967</fpage><lpage>1969</lpage><year>2011</year><pub-id pub-id-type="doi">10.1136/heartjnl-2011-300949</pub-id><pub-id pub-id-type="pmid">21990386</pub-id></element-citation></ref><ref id="b6-etm-0-0-3924"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Avala</surname><given-names>DE</given-names></name><name><surname>Ucieda</surname><given-names>R</given-names></name><name><surname>Hermida</surname><given-names>RC</given-names></name></person-group><article-title>Chronotherapy with low-dose aspirin for prevention of complications in pregnancy</article-title><source>Chronobiol Int</source><volume>9</volume><fpage>1</fpage><lpage>20</lpage><year>2012</year></element-citation></ref><ref id="b7-etm-0-0-3924"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Askie</surname><given-names>LM</given-names></name><name><surname>Duley</surname><given-names>L</given-names></name><name><surname>Henderson-Smart</surname><given-names>DJ</given-names></name><name><surname>Stewart</surname><given-names>LA</given-names></name></person-group><article-title>PARIS Collaborative Group: Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data</article-title><source>Lancet</source><volume>369</volume><fpage>1791</fpage><lpage>1798</lpage><year>2007</year><pub-id pub-id-type="doi">10.1016/S0140-6736(07)60712-0</pub-id><pub-id pub-id-type="pmid">17512048</pub-id></element-citation></ref><ref id="b8-etm-0-0-3924"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramma</surname><given-names>W</given-names></name><name><surname>Ahmed</surname><given-names>A</given-names></name></person-group><article-title>Is inflammation the cause of pre-eclampsia?</article-title><source>Biochem Soc Trans</source><volume>39</volume><fpage>1619</fpage><lpage>1627</lpage><year>2011</year><pub-id pub-id-type="doi">10.1042/BST20110672</pub-id><pub-id pub-id-type="pmid">22103497</pub-id></element-citation></ref><ref id="b9-etm-0-0-3924"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bodnar</surname><given-names>LM</given-names></name><name><surname>Catov</surname><given-names>JM</given-names></name><name><surname>Simhan</surname><given-names>HN</given-names></name><name><surname>Holick</surname><given-names>MF</given-names></name><name><surname>Powers</surname><given-names>RW</given-names></name><name><surname>Roberts</surname><given-names>JM</given-names></name></person-group><article-title>Maternal vitamin D deficiency increases the risk of preeclampsia</article-title><source>J Clin Endocrinol Metab</source><volume>92</volume><fpage>3517</fpage><lpage>3522</lpage><year>2007</year><pub-id pub-id-type="doi">10.1210/jc.2007-0718</pub-id><pub-id pub-id-type="pmid">17535985</pub-id></element-citation></ref><ref id="b10-etm-0-0-3924"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thornton</surname><given-names>CE</given-names></name><name><surname>Makris</surname><given-names>A</given-names></name><name><surname>Ogle</surname><given-names>RF</given-names></name><name><surname>Tooher</surname><given-names>JM</given-names></name><name><surname>Hennessy</surname><given-names>A</given-names></name></person-group><article-title>Role of proteinuria in defining pre-eclampsia: clinical outcomes for women and babies</article-title><source>Clin Exp Pharmacol Physiol</source><volume>37</volume><fpage>466</fpage><lpage>470</lpage><year>2010</year><pub-id pub-id-type="doi">10.1111/j.1440-1681.2009.05334.x</pub-id><pub-id pub-id-type="pmid">19930427</pub-id></element-citation></ref><ref id="b11-etm-0-0-3924"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>P</given-names></name><name><surname>Brown</surname><given-names>M</given-names></name><name><surname>Simpson</surname><given-names>JM</given-names></name><name><surname>Davis</surname><given-names>G</given-names></name></person-group><article-title>Proteinuria in pre-eclampsia: how much matters?</article-title><source>BJOG</source><volume>112</volume><fpage>280</fpage><lpage>285</lpage><year>2005</year><pub-id pub-id-type="doi">10.1111/j.1471-0528.2004.00395.x</pub-id><pub-id pub-id-type="pmid">15713140</pub-id></element-citation></ref><ref id="b12-etm-0-0-3924"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newman</surname><given-names>MG</given-names></name><name><surname>Robichaux</surname><given-names>AG</given-names></name><name><surname>Stedman</surname><given-names>CM</given-names></name><name><surname>Jaekle</surname><given-names>RK</given-names></name><name><surname>Fontenot</surname><given-names>MT</given-names></name><name><surname>Dotson</surname><given-names>T</given-names></name><name><surname>Lewis</surname><given-names>DF</given-names></name></person-group><article-title>Perinatal outcomes in preeclampsia that is complicated by massive proteinuria</article-title><source>Am J Obstet Gynecol</source><volume>188</volume><fpage>264</fpage><lpage>268</lpage><year>2003</year><pub-id pub-id-type="doi">10.1067/mob.2003.84</pub-id><pub-id pub-id-type="pmid">12548227</pub-id></element-citation></ref><ref id="b13-etm-0-0-3924"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spinnato</surname><given-names>JA</given-names><suffix>II</suffix></name><name><surname>Freire</surname><given-names>S</given-names></name><name><surname>Pinto</surname><given-names>E</given-names></name><name><surname>Silva</surname><given-names>JL</given-names></name><name><surname>Rudge</surname><given-names>MV Cunha</given-names></name><name><surname>Martins-Costa</surname><given-names>S</given-names></name><name><surname>Koch</surname><given-names>MA</given-names></name><name><surname>Goco</surname><given-names>N</given-names></name><name><surname>Santos</surname><given-names>CB</given-names></name><name><surname>Cecatti</surname><given-names>JG</given-names></name><name><surname>Costa</surname><given-names>R</given-names></name><etal/></person-group><article-title>Antioxidant therapy to prevent preeclampsia: a randomized controlled trial</article-title><source>Obstet Gynecol</source><volume>110</volume><fpage>1311</fpage><lpage>1318</lpage><year>2007</year><pub-id pub-id-type="doi">10.1097/01.AOG.0000289576.43441.1f</pub-id><pub-id pub-id-type="pmid">18055726</pub-id></element-citation></ref><ref id="b14-etm-0-0-3924"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Benavides</surname><given-names>L</given-names></name><name><surname>Guzman-Sanchez</surname><given-names>A</given-names></name><name><surname>Hernandez-Mora</surname><given-names>FJ</given-names></name><name><surname>Muro-Gomez</surname><given-names>AM</given-names></name><name><surname>Gomez-Martinez</surname><given-names>ML</given-names></name><name><surname>Siller-Lopez</surname><given-names>FR</given-names></name></person-group><article-title>PP078. Total antioxidant capacity in patients with pregnancy induced hypertension: its relation to maternal and/or perinatal complications</article-title><source>Pregnancy Hypertens</source><volume>2</volume><fpage>282</fpage><lpage>283</lpage><year>2012</year><pub-id pub-id-type="pmid">26105400</pub-id></element-citation></ref><ref id="b15-etm-0-0-3924"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdolvahabi</surname><given-names>A</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Rhodes</surname><given-names>NR</given-names></name><name><surname>Cook</surname><given-names>NP</given-names></name><name><surname>Marti</surname><given-names>AA</given-names></name><name><surname>Shaw</surname><given-names>BF</given-names></name></person-group><article-title>Arresting amyloid with coulomb's law: Acetylation of ALS-linked SOD1 by aspirin impedes aggregation</article-title><source>Biophys J</source><volume>108</volume><fpage>1199</fpage><lpage>1212</lpage><year>2015</year><pub-id pub-id-type="doi">10.1016/j.bpj.2015.01.014</pub-id><pub-id pub-id-type="pmid">25762331</pub-id></element-citation></ref><ref id="b16-etm-0-0-3924"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bujold</surname><given-names>E</given-names></name></person-group><article-title>Prevention of pre-eclampsia with low-dose aspirin</article-title><source>J Postgrad Med</source><volume>57</volume><fpage>89</fpage><lpage>90</lpage><year>2011</year><pub-id pub-id-type="doi">10.4103/0022-3859.81857</pub-id><pub-id pub-id-type="pmid">21654127</pub-id></element-citation></ref><ref id="b17-etm-0-0-3924"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jain</surname><given-names>A</given-names></name></person-group><article-title>Endothelin-1: a key pathological factor in pre-eclampsia?</article-title><source>Reprod Biomed Online</source><volume>25</volume><fpage>443</fpage><lpage>449</lpage><year>2012</year><pub-id pub-id-type="doi">10.1016/j.rbmo.2012.07.014</pub-id><pub-id pub-id-type="pmid">22995748</pub-id></element-citation></ref><ref id="b18-etm-0-0-3924"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>GS</given-names></name><name><surname>Allshouse</surname><given-names>AA</given-names></name><name><surname>Winn</surname><given-names>VD</given-names></name><name><surname>Galan</surname><given-names>HL</given-names></name><name><surname>Heyborne</surname><given-names>KD</given-names></name></person-group><article-title>Baseline placental growth factor levels for the prediction of benefit from early aspirin prophylaxis for preeclampsia prevention</article-title><source>Pregnancy Hypertens</source><volume>5</volume><fpage>280</fpage><lpage>286</lpage><year>2015</year><pub-id pub-id-type="pmid">26597741</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap id="tI-etm-0-0-3924" orientation="portrait" position="float"><label>Table I.</label><caption><p>Comparison of MAP, pre-eclampsia rate, gestational weeks and caesarean section.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Groups</th><th align="center" valign="bottom" rowspan="1" colspan="1">Cases</th><th align="center" valign="bottom" rowspan="1" colspan="1">Before MAP (mmHg)</th><th align="center" valign="bottom" rowspan="1" colspan="1">After MAP</th><th align="center" valign="bottom" rowspan="1" colspan="1">Pre-eclampsia</th><th align="center" valign="bottom" rowspan="1" colspan="1">Gestational week (weeks)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Caesarean section</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Control</td><td align="center" valign="top" rowspan="1" colspan="1">50</td><td align="center" valign="top" rowspan="1" colspan="1">115.8&#x000b1;15.9</td><td align="center" valign="top" rowspan="1" colspan="1">88.2&#x000b1;13.2</td><td align="center" valign="top" rowspan="1" colspan="1">16 (32.0)</td><td align="center" valign="top" rowspan="1" colspan="1">35.6&#x000b1;3.3</td><td align="center" valign="top" rowspan="1" colspan="1">6 (12.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">50 mg/day</td><td align="center" valign="top" rowspan="1" colspan="1">60</td><td align="center" valign="top" rowspan="1" colspan="1">117.6&#x000b1;16.7</td><td align="center" valign="top" rowspan="1" colspan="1">86.4&#x000b1;14.6</td><td align="center" valign="top" rowspan="1" colspan="1">22 (36.7)</td><td align="center" valign="top" rowspan="1" colspan="1">36.4&#x000b1;3.5</td><td align="center" valign="top" rowspan="1" colspan="1">7 (11.7)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">75 mg/day</td><td align="center" valign="top" rowspan="1" colspan="1">58</td><td align="center" valign="top" rowspan="1" colspan="1">114.4&#x000b1;18.2</td><td align="center" valign="top" rowspan="1" colspan="1">85.8&#x000b1;12.7</td><td align="center" valign="top" rowspan="1" colspan="1">20 (34.5)</td><td align="center" valign="top" rowspan="1" colspan="1">36.2&#x000b1;3.6</td><td align="center" valign="top" rowspan="1" colspan="1">8 (13.8)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">100 mg/day</td><td align="center" valign="top" rowspan="1" colspan="1">56</td><td align="center" valign="top" rowspan="1" colspan="1">109.2&#x000b1;20.2</td><td align="center" valign="top" rowspan="1" colspan="1">86.6&#x000b1;16.9</td><td align="center" valign="top" rowspan="1" colspan="1">21 (37.5)</td><td align="center" valign="top" rowspan="1" colspan="1">35.8&#x000b1;3.7</td><td align="center" valign="top" rowspan="1" colspan="1">7 (12.5)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">F</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.526</td><td align="center" valign="top" rowspan="1" colspan="1">0.637</td><td align="center" valign="top" rowspan="1" colspan="1">0.423</td><td align="center" valign="top" rowspan="1" colspan="1">0.836</td><td align="center" valign="top" rowspan="1" colspan="1">0.138</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">P-value</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.325</td><td align="center" valign="top" rowspan="1" colspan="1">0.421</td><td align="center" valign="top" rowspan="1" colspan="1">0.935</td><td align="center" valign="top" rowspan="1" colspan="1">0.725</td><td align="center" valign="top" rowspan="1" colspan="1">0.987</td></tr></tbody></table></table-wrap><table-wrap id="tII-etm-0-0-3924" orientation="portrait" position="float"><label>Table II.</label><caption><p>Comparison of 24-h urinary protein, SOD and ET-1.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th align="center" valign="bottom" colspan="4" rowspan="1">24-h urinary protein (g)</th><th align="center" valign="bottom" colspan="4" rowspan="1">SOD (nU/ml)</th><th align="center" valign="bottom" colspan="4" rowspan="1">ET-1 (ng/l)</th></tr><tr><th rowspan="1" colspan="1"/><th align="center" valign="bottom" colspan="4" rowspan="1"><hr/></th><th align="center" valign="bottom" colspan="4" rowspan="1"><hr/></th><th align="center" valign="bottom" colspan="4" rowspan="1"><hr/></th></tr><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Groups</th><th align="center" valign="bottom" rowspan="1" colspan="1">Before</th><th align="center" valign="bottom" rowspan="1" colspan="1">After</th><th align="center" valign="bottom" rowspan="1" colspan="1">t</th><th align="center" valign="bottom" rowspan="1" colspan="1">P-value</th><th align="center" valign="bottom" rowspan="1" colspan="1">Before</th><th align="center" valign="bottom" rowspan="1" colspan="1">After</th><th align="center" valign="bottom" rowspan="1" colspan="1">t</th><th align="center" valign="bottom" rowspan="1" colspan="1">P-value</th><th align="center" valign="bottom" rowspan="1" colspan="1">Before</th><th align="center" valign="bottom" rowspan="1" colspan="1">After</th><th align="center" valign="bottom" rowspan="1" colspan="1">t</th><th align="center" valign="bottom" rowspan="1" colspan="1">P-value</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Control</td><td align="center" valign="top" rowspan="1" colspan="1">2.3&#x000b1;0.9</td><td align="center" valign="top" rowspan="1" colspan="1">1.8&#x000b1;0.5</td><td align="center" valign="top" rowspan="1" colspan="1">1.201</td><td align="center" valign="top" rowspan="1" colspan="1">0.967</td><td align="center" valign="top" rowspan="1" colspan="1">46.7&#x000b1;13.5</td><td align="center" valign="top" rowspan="1" colspan="1">53.4&#x000b1;15.2</td><td align="center" valign="top" rowspan="1" colspan="1">0.637</td><td align="center" valign="top" rowspan="1" colspan="1">0.432</td><td align="center" valign="top" rowspan="1" colspan="1">86.5&#x000b1;20.1</td><td align="center" valign="top" rowspan="1" colspan="1">83.4&#x000b1;26.9</td><td align="center" valign="top" rowspan="1" colspan="1">0.467</td><td align="center" valign="top" rowspan="1" colspan="1">0.102</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">50 mg/day</td><td align="center" valign="top" rowspan="1" colspan="1">2.4&#x000b1;0.8</td><td align="center" valign="top" rowspan="1" colspan="1">1.6&#x000b1;0.7</td><td align="center" valign="top" rowspan="1" colspan="1">1.367</td><td align="center" valign="top" rowspan="1" colspan="1">0.768</td><td align="center" valign="top" rowspan="1" colspan="1">48.2&#x000b1;14.9</td><td align="center" valign="top" rowspan="1" colspan="1">55.9&#x000b1;16.9</td><td align="center" valign="top" rowspan="1" colspan="1">0.938</td><td align="center" valign="top" rowspan="1" colspan="1">0.558</td><td align="center" valign="top" rowspan="1" colspan="1">85.2&#x000b1;23.5</td><td align="center" valign="top" rowspan="1" colspan="1">81.6&#x000b1;23.5</td><td align="center" valign="top" rowspan="1" colspan="1">0.539</td><td align="center" valign="top" rowspan="1" colspan="1">0.325</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">75 mg/day</td><td align="center" valign="top" rowspan="1" colspan="1">2.5&#x000b1;0.7</td><td align="center" valign="top" rowspan="1" colspan="1">0.9&#x000b1;0.4</td><td align="center" valign="top" rowspan="1" colspan="1">4.938</td><td align="center" valign="top" rowspan="1" colspan="1">0.039</td><td align="center" valign="top" rowspan="1" colspan="1">46.9&#x000b1;16.3</td><td align="center" valign="top" rowspan="1" colspan="1">127.4&#x000b1;34.5</td><td align="center" valign="top" rowspan="1" colspan="1">5.634</td><td align="center" valign="top" rowspan="1" colspan="1">0.035</td><td align="center" valign="top" rowspan="1" colspan="1">88.4&#x000b1;24.6</td><td align="center" valign="top" rowspan="1" colspan="1">48.5&#x000b1;14.7</td><td align="center" valign="top" rowspan="1" colspan="1">6.324</td><td align="center" valign="top" rowspan="1" colspan="1">0.028</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">100 mg/day</td><td align="center" valign="top" rowspan="1" colspan="1">2.3&#x000b1;0.8</td><td align="center" valign="top" rowspan="1" colspan="1">1.1&#x000b1;0.6</td><td align="center" valign="top" rowspan="1" colspan="1">5.022</td><td align="center" valign="top" rowspan="1" colspan="1">0.037</td><td align="center" valign="top" rowspan="1" colspan="1">47.5&#x000b1;18.5</td><td align="center" valign="top" rowspan="1" colspan="1">113.8&#x000b1;33.6</td><td align="center" valign="top" rowspan="1" colspan="1">5.705</td><td align="center" valign="top" rowspan="1" colspan="1">0.033</td><td align="center" valign="top" rowspan="1" colspan="1">87.5&#x000b1;28.7</td><td align="center" valign="top" rowspan="1" colspan="1">46.3&#x000b1;16.9</td><td align="center" valign="top" rowspan="1" colspan="1">6.532</td><td align="center" valign="top" rowspan="1" colspan="1">0.023</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">F</td><td align="center" valign="top" rowspan="1" colspan="1">0.635</td><td align="center" valign="top" rowspan="1" colspan="1">5.624</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.837</td><td align="center" valign="top" rowspan="1" colspan="1">5.768</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.584</td><td align="center" valign="top" rowspan="1" colspan="1">6.967</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">P-value</td><td align="center" valign="top" rowspan="1" colspan="1">0.427</td><td align="center" valign="top" rowspan="1" colspan="1">0.033</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.639</td><td align="center" valign="top" rowspan="1" colspan="1">0.031</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.323</td><td align="center" valign="top" rowspan="1" colspan="1">0.015</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-etm-0-0-3924"><p>SOD, superoxide dismutase; ET-1, endothelin-1.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tIII-etm-0-0-3924" orientation="portrait" position="float"><label>Table III.</label><caption><p>Comparison of complications during the perinatal period (cases %).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Groups</th><th align="center" valign="bottom" rowspan="1" colspan="1">Cases</th><th align="center" valign="bottom" rowspan="1" colspan="1">Intracranial and ventricular hemorrhage</th><th align="center" valign="bottom" rowspan="1" colspan="1">Ischemia, hypoxia</th><th align="center" valign="bottom" rowspan="1" colspan="1">Placental abruption</th><th align="center" valign="bottom" rowspan="1" colspan="1">Death</th><th align="center" valign="bottom" rowspan="1" colspan="1">Complication rate</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Control</td><td align="center" valign="top" rowspan="1" colspan="1">50</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">4 (8.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">50 mg/day</td><td align="center" valign="top" rowspan="1" colspan="1">60</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">5 (8.3)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">75 mg/day</td><td align="center" valign="top" rowspan="1" colspan="1">58</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">6 (10.3)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">100 mg/day</td><td align="center" valign="top" rowspan="1" colspan="1">56</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">5 (8.9)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x003c7;<sup>2</sup></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.218</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">P-value</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.975</td></tr></tbody></table></table-wrap></floats-group></article>